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This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral
therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More
than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next
12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical
considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI
in the context of circulating SARS-CoV-2.Introduction
Control of HIV replication using antiretroviral therapy (ART) has
transformed survival for people living with HIV.1,2 Viral suppression
enables immune recovery3 and limits the risk of onward viral trans-
mission4,5 but requires lifelong adherence to ART,6 which presents a
challenge to some and a major constraint to healthcare systems, partic-
ularly in resource-limited settings.7 Potential HIV remission or cure is a
recognised goal of both researchers and the community of people living
with HIV.8
Interruption of ART usually leads to a rapid return of viraemia within
2–6 weeks of stopping medication.9,10 Long-lived cells that harbour
replication-competent HIV (the “HIV reservoir”)11 are the source of this
rebounding virus. Whilst there are many laboratory-based assays that
measure the size, location and characteristics of the HIV reservoir,12 to
date none have been shown to accurately predict the risk of viral rebound
upon stopping ART. It is for this reason that clinical trials exploring the
ability of novel strategies to maintain viral control off ART usuallyr).
m 4 December 2020; Accepted 4
is an open access article under trequire a carefully monitored analytical treatment interruption (ATI).
The ATI protocols require a rigorous clinical, ethical and practical eval-
uation to determine risk mitigation for participants and their sexual
partners, as well as the evaluation of the commitment to regular HIV viral
load measurements. Conducting an ATI, even in the absence of a dynamic
global pandemic, is challenging,13 but there are now standard ap-
proaches and a general consensus on how these studies should be per-
formed.14 Conducting an ATI during the COVID-19 pandemic raises
many additional issues that will need to be addressed by clinicians, the
community, funders and regulators.
Since December 2019 the global SARS-CoV-2 pandemic has dramat-
ically altered daily lives,14 medical care and research.15 Limitation of
travel and physical distancing were universally adopted, leading to a new
clinical environment designed to minimize people’s exposure to the
health care system. The manner in which care has been provided for
people living with HIV has also had to change. To help define policies,
many countries drew up guidelines to inform management and care for
people living with HIV, whilst SARS-CoV-2 continued to circulate at
significant levels.16 At the same time, all non-COVID-19-related clinical
research was paused, diverting resources to the COVID-19 response. As
the pandemic continues, we need to carefully re-evaluate the risks and
benefits of resuming HIV clinical trials, even those including an ATI.December 2020
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As the impact of SARS-CoV-2 declines, it will be possible to restart
answering important research questions for the 39 million people glob-
ally living with HIV. Generally, most people still hope for an HIV cure.
Cure studies need to optimise safety for participants, but also maintain
maximal scientific rigor through continued engagement among all
stakeholders to ensure that any risk to participants i can also be justified
by the potential benefit to the larger community.17
The ethical debate about the pros and cons of an indefinite deferral
versus careful resumption of ATI HIV cure studies is important. One
option is to indefinitely stop all HIV trials including an ATI until there is a
widely available SARS-CoV-2 prophylactic vaccine18 or effective treat-
ment for COVID-19 disease.19 Whilst there is a global commitment to
both of these goals, the potential for delay with this option is high and
many ground-breaking novel HIV remission therapies and approaches
currently in trial would remain paused. In the meantime, challenges
continue for people living with HIV globally to receive and adhere to
reliable, sustainable and programmatic delivery of daily ART,20 further
threatened by ongoing COVID-related clinical burden and limitation of
movement of people, drugs and reagents.
If HIV cure and ATI trials are to continue, each individual study will
need to be reviewed and evaluated on a case-by-case basis, once back-
ground COVID-19 incidence drops to low levels, as yet undefined.
Common mitigation approaches to reduce risk within the field of HIV
cure and remission trials might provide a framework to safely reinstitute
ATI studies. This will require changes to patient information and
informed consent so that study participants are aware of the implications
from COVID-19.
Preservation of trial scientific integrity to retain the capacity to
generate meaningful data is critical. Exclusion of participants or alter-
ation of study outcomes (eg viral control off ART), to mitigate COVID-19
risk that might compromise trial rigor, could undermine the value of
continuing such research in the current climate. Besides being able to
ensure adequate HIV viral load monitoring to generate sufficient data
points for analysis, a reality that cure studies may have to face is to
consider alternative primary endpoints to HIV viral load, (e.g. if partic-
ipants need to re-initiate ART because of acquiring SARS-CoV-2 infec-
tion, exposure, inability to travel). Studies may need to be re-designed
around the “imperfect” other measurements of immune responses and
HIV reservoir, as back up.
Risk of SARS-CoV-2 acquisition amongst people living with HIV
The overall risk of SARS-CoV-2 acquisition is largely related to
exposure. This will vary based on: (i) local incidence, (ii) physical cir-
cumstances (proximity to people with SARS-CoV-2), (iii) behavioural
factors (distancing, masks and hand washing, etc), and (iv) individual
susceptibility to SARS-CoV-2 acquisition, including level of immune
suppression. There is no evidence to date showing that people living with
HIV on ART are at significantly increased risk of SARS-Cov-2 acquisition
compared to HIV negative people21 or to determine whether HIV vir-
aemia increases the risk of SARS-CoV-2 acquisition. Therefore, there are
theoretical concerns that uncontrolled HIV might increase the risk of
SARS-CoV-2 infection, predominantly weighted around the concern of
decreased immunity due to a low CD4 T cell count rather than evidence
for increased risk specifically caused by HIV viraemia. The current
recommendation is, therefore, that all people living with HIV should be
on ART.22
Risk of more severe COVID-19 disease amongst people living with
HIV
Severe COVID-19 disease has been associated with many risk factors.
These include: older age (>60 years), male gender and comorbidities
(including cardiovascular and renal disease, hypertension, diabetes,2
obesity, ongoing cancer and recent organ recipients).23 Poverty, poor
housing, minority ethnic populations and other linked socioeconomic
factors are important risk factors for more severe disease.24 Many of the
socioeconomic, ethnicity and comorbidity risks are over-represented
amongst the population of PLWH.
To date there is limited but increasing data on the absolute risk of
severe COVID-19 for people living with HIV.25–30 Most studies have
found no evidence of an increased risk of COVID-19-related death in
people living with HIV, once co-morbidities are taken into account.29
One large study of HIV/COVID-19 coinfections in South Africa reported a
2-fold increase in mortality associated with HIV, but acknowledged that
the data could be largely explained by confounding factors in this pop-
ulation.30 However, again the quality of evidence for those who were
viremic or not on ART is less good, and, although no clear risks have been
identified, this caveat needs to be considered.
Specific considerations associated with ATI in SARS-CoV-2 pandemic:
1. Risks associated with taking part into a clinical trial which
usually require additional hospital visits and procedures that could be
associated with higher risk of SARS-CoV-2 acquisition.
2. Risk of increased susceptibility to SARS-CoV-2 associated with
the ATI due to HIV-associated inflammation and immunodeficiency,
which may hypothetically increase the risk of acquisition after
exposure.
3. Risk of a worse clinical outcome from COVID-19 disease: acute
SARS-CoV-2 infection causes lymphopenia and this in turn is associ-
ated with a poor outcome.23 There is a hypothetical increased risk of
severe COVID-19 disease for people living with HIV undertaking an
ATI due to a possible increased susceptibility to immune activation
and a ‘cytokine storm’31 during an ATI-induced viral rebound.
Because of ATI trial closures, there is no data at present showing that
this is the case, but this cannot infer safety. This potential risk may be
further accentuated in cure ATI studies involving immune-enhancing
interventions (e.g. broadly neutralizing antibodies, therapeutic HIV
vaccines, toll-like receptor agonists), although at this stage this re-
mains a theoretical risk in the absence of data.
4. Risk of a worse outcome of the ATI: the ATI itself has been asso-
ciated with increased levels of inflammation related to adverse
events. Acquisition of SARS-CoV-2 infection during an ATI might be
an additional trigger for inflammation32 and increase the risk of
ATI-related cardiovascular events.33 ATI studies may exclude partic-
ipants at higher risk of inflammation-related complications.
5. Risk of disruption to ART availability could severely impact ATI
studies if drugs are not available for ART resumption, which may
influence some settings more than others. The challenges in resource-
limited and high HIV burden settings are driven by limited global
manufacturer production capacities and global supply chain disrup-
tions, coupled with limited access to health services within countries
as a result of the COVID-19 pandemic.34
Suggested risk mitigation strategies for recommencing studies
with an ATI in the setting of COVID-19 (Table 1)
Assuming that there will remain consensus that HIV ATI studies are
ethical and should continue we would like to explore how they might be
safely implemented. Should an effective SARS-CoV-2 vaccine become
available during the implementation of an HIV cure trial, vaccination
should be recommended for all study participants and ideally prior to an
ATI.
We propose the following mitigation considerations prior to enrol-
ment into ATI studies in the absence of a SARS-CoV-2 prophylactic
vaccine or effective treatment:
Modification of study eligibility criteria







Increased risk of severe
COVID-19 disease
Evaluation of severe COVID-








issues – i.e. limiting
research by ethnicity or
employment.
Risk of severe COVID-
19 if acquired at time
of any high-risk
curative intervention
SARS-CoV-2 PCR test prior
to administration of any
therapy that might alter the
risk of COVID-19 disease.
Ensure rapid access to
PCR and results – ideally
POCT testing on same
day.
Risk of severe COVID-
19 if acquired at time
of an ATI
SARS-CoV-2 PCR test on day
of enrolment into ATI
protocol.
Ensure rapid access to
PCR and results – ideally
if available POCT testing
on same day.
Risk of severe COVID-
19 if acquired during
an ATI
Offer rapid SARS-Cov-2 PCR
throughout ATI period,
screen all symptomatic
participants and rapid re-
start of ART if PCRþ
Restart ART if high risk
SARS-CoV-2 exposure
during an ATI: e.g. if
household contact becomes
COVIDþ.
Ensure rapid access to
PCR and results – ideally
POCT testing on same
day.
Challenge to study power
if many have to re-start





visits for blood draws
Limit number of visits for VL
measurement.
Evaluate novel point of care
or self-sampling blood for
VL (DBS) and possible role
of community blood draw
teams for household
research staff visits.
Often an HIV VL is the
study primary endpoint.
It is important to ensure
capture of sufficient and
high quality data to
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factors (e.g. age, diabetes mellitus, hypertension, and obesity) based on
data from large population studies.23 Flu vaccination is recommended
prior to enrolment dependent on season availability.
SARS-CoV-2 testing at study entry
Enrolment should be limited to those without symptoms who test
negative on SARS-CoV-2 PCR prior to study implementation.
For anyone testing SARS-CoV-2 PCR positive and excluded from
enrolment, once repeat testing is negative, they may then be eligible to
join the study.
At present, there is not enough data in terms of SARS-CoV-2 sero-
logical assays to be useful decision-making tools for trial eligibility,35
although further validation could direct eligibility in the future.
SARS-Cov-2 testing through the ATI period
Vigilance will be recommended for all study participants in terms of
symptoms associated with COVID-19 throughout the ATI period.
SARS-CoV-2 testing will be offered to all study participants who3
report any symptoms suggestive of infection.36
SARS-Cov-2 PCR testing will also be offered to all study participants
in close contact with a confirmed COVID-19 case identified through
contact tracing procedures or direct household contacts.
Despite a participant testing negative for SARS-CoV-2 PCR, if a
household member or close contact is diagnosed SARS-CoV-2 positive,
isolation is required for a 14 day-quarantine period after exposure.
Repeat testing will be offered as needed and attendance for hospital visits
will be deferred during this time.
Modification of HIV viral load testing strategies during ATI
During periods of increased SARS-CoV-2 incidence in the immediate
communities, relaxation of frequency of hospital attendances for HIV
viral load testing could be made or household blood draws for those
study participants who prefer this option. For example, in protocols with
an initial weekly plasma viral load test following commencement of ATI,
this could be relaxed to a fortnightly one.
Exploration of alternative types of viral load measurements such as
using self-taken finger prick blood samples that might be sent directly to
a laboratory for assessment.37
Exclusion of acute SARS-CoV-2 infection at commencement of a curative
interventions (e.g., chemotherapy in transplant protocols, most
immunotherapies) and prior to the ATI
Swab for PCR within 48 h or ideally a point of care SARS-CoV-2 PCR
assay prior to any experimental therapy that might alter the risk of
COVID-19 and on the day of ATI start, to exclude acute infection.
Screening for symptoms (anosmia, cough, fever, myalgia, and head-
ache) to occur at all ATI visits and by telephone consultation for missed
or deferred visits.
Any individual testing SARS-CoV-2 positive can defer enrolment until
the infection has cleared and rejoin study enrolment at a later date.
Review of ART re-start criteria if SARS-CoV-2 PCR positivity
Re-start of ART will be recommended in the presence of symptoms
and a SARS-Cov-2 PCR positive test result. Symptoms alone would not
trigger ART re-start, unless severe.This will be an important decision to
be made on an individual participant basis in discussion with the trial
physician. Depending on the individual and the trial protocol, ATI might
recommence once symptoms resolve and the PCR result has become
negative.
Sensitivity to changes in local SARS-CoV-2 risk
As exposure is the main factor driving risk of infection, the back-
ground incidence of SARS-CoV-2 will need to be low enough for local
lockdown measures to have been lifted. While this might be clear at
enrolment, it is not possible to predict during the course of the study how
this might change. Strategies will need to adapt to changes in local and
regional resurgences of COVID-19. An independent committee might be
assembled to provide investigators with advice on when local conditions
might result in a study being paused or terminated.
Informed consent. Ensuring consistent and thorough participant in-
formation should include recent COVID-19 data and concerns relating to
COVID-19 as well as the ways that the research has been modified to
reduce risks. We propose that a COVID-19 risk assessment tool should be
recommended as part of the informed consent procedure.
Community perspective and interest in ATI participation in the
time of COVID
There will be different community and also researchers views on the
safest way to continue with studies that involve an ATI.
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As this paper was in press, the first reports of high levels of vaccine
protection (both at >90%) were reported from the Pfizer/BioNTech39
and Moderna/NIH40 phase 3 studies and the Oxford/Astrozeneca trial41
(>70%). The data is yet to be published in peer reviewed journals and
data on vaccine safety and efficacy in PLWH remains unknown. However,
provided the SARS-CoV-2 protection and immune responses are durable
and confirmed with longer-term follow-up, then access to these or sub-
sequent vaccines will dramatically change the risk:benefit of both
running and participating in research that involves an ATI. The choice to
access a vaccine might therefore be added to research protocols and/or
having received a vaccine prior to study enrolment and ideally prior to
ATI might be added to inclusion criteria.
Conclusion
The HIV global epidemic continues to be present during the COVID-
19 pandemic, and whilst focus must clearly shift to ensure above all
else the preservation of health and safety of people living with HIV, there
remains a commitment and drive from the communities and researchers
to pursue novel and optimal long-term therapies.37 This discussion
document summarises potential risks and suggests pragmatic mitigation
strategies to allow the safe re-opening of HIV intervention trials that
include an ATI once the absolute risk of COVID-19 is manageable. The
approaches suggested here will be impacted by circumstantial
SARS-CoV-2 prevalence and incidence as well as the availability of
treatments and a prophylactic vaccine.
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